DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma by Zhang, Geng et al.
DPEP1 Inhibits Tumor Cell Invasiveness, Enhances











4, Harris G. Yfantis





7, H. Richard Alexander
7, S. Perwez Hussain
1*
1Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, United States of
America, 2Department of General and Visceral Surgery, University Medicine, Go ¨ttingen, Germany, 3Genetics Branch, National Cancer Institute, NIH, Bethesda, Maryland,
United States of America, 4Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, United States of America, 5Pathology and Laboratory
Medicine, Baltimore Veterans Affairs Medical Center, Baltimore, Maryland, United States of America, 6The Sol Goldman Pancreatic Cancer Research Center, School of
Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, 7Division of Surgical Oncology, The Department of Surgery and the Marlene, School of
Medicine, Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States of America
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. To identify biologically relevant
genes with prognostic and therapeutic significance in PDAC, we first performed the microarray gene-expression profiling in
45 matching pairs of tumor and adjacent non-tumor tissues from resected PDAC cases. We identified 36 genes that were
associated with patient outcome and also differentially expressed in tumors as compared with adjacent non-tumor tissues
in microarray analysis. Further evaluation in an independent validation cohort (N=27) confirmed that DPEP1 (dipeptidase 1)
expression was decreased (T: N ratio ,0.1, P,0.01) in tumors as compared with non-tumor tissues. DPEP1 gene expression
was negatively correlated with histological grade (Spearman correlation coefficient=20.35, P=0.004). Lower expression of
DPEP1 in tumors was associated with poor survival (Kaplan Meier log rank) in both test cohort (P=0.035) and validation
cohort (P=0.016). DPEP1 expression was independently associated with cancer-specific mortality when adjusted for tumor
stage and resection margin status in both univariate (hazard ratio=0.43, 95%CI=0.24–0.76, P=0.004) and multivariate
analyses (hazard ratio=0.51, 95%CI=0.27–0.94, P=0.032). We further demonstrated that overexpression of DPEP1
suppressed tumor cells invasiveness and increased sensitivity to chemotherapeutic agent Gemcitabine. Our data also
showed that growth factor EGF treatment decreased DPEP1 expression and MEK1/2 inhibitor AZD6244 increased DPEP1
expression in vitro, indicating a potential mechanism for DPEP1 gene regulation. Therefore, we provide evidence that DPEP1
plays a role in pancreatic cancer aggressiveness and predicts outcome in patients with resected PDAC. In view of these
findings, we propose that DPEP1 may be a candidate target in PDAC for designing improved treatments.
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Introduction
PDAC is the fourth leading cause of cancer deaths in the United
States and is among the most lethal human malignancies
worldwide with a median survival of 6 months and 5-year survival
of 6% [1]. An estimated 44,030 new cases and 37,660 deaths are
expected to occur in the United States in 2011(American Cancer
Society, Cancer Facts & Figures 2011). The dismal outcome in
pancreatic cancer patients is attributed to the late diagnosis and
resistance to the available chemotherapy. In less than 20% of the
patients, surgical resection is an option with some potential for
cure. The median survival even for resected patients is less than 2
years with recurrence in ,80% of the cases within this time
period. However, about 12% of the resected patients may survive
for 5 years, which is attributed not only to the stage, grade and
resection margin status but also to the distinct biological makeup
of tumors [2,3].
Gemcitabine is the first-line chemotherapeutic drug commonly
used for advanced pancreatic cancer. However, single agent
gemcitabine is only moderately effective with a tumor response
rate of ,12% [4]. In a recent phase 3 trial, FOLFIRINOX
regimen (oxaliplatin, irinotecan, fluorouracil and leucovorin)
significantly enhanced median survival as compared to gemcita-
bine (11.1 vs. 6.8 months, P,0.001), in patients with metastatic
pancreatic cancer [5]. Despite recent progress in chemotherapy,
better understanding of molecular mechanism of this disease and
discovery of novel therapeutic targets are desperately needed to
improve outcomes in patients with PDAC.
One strategy to identify the potential targets for pancreatic
cancer treatments is to distinguish and investigate genes and
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relevant to the aggressiveness of PDAC [2]. Gene-expression
profiling using microarrays has been utilized to identify genes or
gene signatures that are associated with pancreatic cancer [6,7,8].
A few studies have defined and validated gene signatures that are
associated with survival, pathological stage and metastasis using
microarrays, providing insight into molecular subtypes of PDAC
and revealing several promising targets for cancer treatment
[9,10,11]. In the present study, we first identified genes that were
associated with cancer-specific mortality by microarray gene
expression analysis and validated them by quantitative RT-PCR
in two independent cohorts of resected PDAC cases. We then
explored the biological function of DPEP1, a predictor of patient
outcome identified in our study, revealing its potential therapeutic
significance in pancreatic cancer.
Materials and Methods
Tissue Collection
Matched pairs of primary pancreatic tumor and adjacent non-
tumor tissues came from 45 patients with PDCA at the University
of Medicine, Go ¨ttingen, Germany, and from 27 patients
recruited from the University of Maryland Medical System
(UMMS) at Baltimore, Maryland through NCI-UMD resource
contract. Tissues were flash frozen immediately after surgery.
Demographic and clinical information for each tissue donor,
including age, sex, clinical staging, resection margin status,
survival times from diagnosis, and receipt of adjuvant chemo-
therapy were collected. Tumor histopathology was classified
according to the World Health Organization Classification of
Tumor system [12]. Use of these clinical specimens was reviewed
by the NCI-Office of the Human Subject Research (OHSR,
Exempt # 4678) at the National Institutes of Health, Bethesda,
MD.
RNA Isolation and Microarray Processing
RNA from frozen tissue samples was extracted using standard
TRIZOL (Invitrogen) protocol. RNA quality was confirmed
with the Agilent 2100 Bioanalyzer (Agilent Technologies) before
the microarray gene expression profiling. Tumors and paired
non-tumor tissues from Germany cohort were profiled using the
Affymetrix GeneChip Human 1.0 ST arrays according to the
manufacturer’s protocol at LMT microarray core facility at
National Cancer Institute, Frederick, MD. All arrays were RMA
normalized and gene expression summaries were created for
each gene by averaging all probe sets for each gene using Partek
Genomics Suite 6.5. All data analysis was performed on gene
summarized data. The microarray gene expression data has
been deposited in the National Center for Biotechnology
Information’s (NCBIs) Gene Expression Omnibus (GEO;
http://www.ncbi.nlm.nih.gov/geo) with accession numbers
GSE28735.
Quantitative RT-PCR (qRT-PCR)
Total RNA was reverse transcribed using High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems). High-
throughput qRT-PCR of gene expression was performed using
96.96 dynamic array chips from Fluidigm Corporation accord-
ing to the manufacturer’s protocol. Pre-amplification reactions
were done in a GeneAmp PCR System 9700 from Applied
Biosystems. The IFC Controller HX (Fluidigm Corporation)
utilizes pressure to control the valves in the chips and load
samples and gene expression assay reagents into the reaction
chambers. The BioMark system (Fluidigm Corporation) is a real-
time PCR instrument designed to thermal cycle these micro-
fluidic chips and image the data in real time. qRT-PCR
reactions in 384 well plates were performed using Taqman Gene
Expression Assays on an ABI Prism 7900HT Sequence
Detection instrument from Applied Biosystems. Expression levels
of GAPDH were used as the endogenous controls. All assays
were performed in quadruplates or triplicates. For quality
control, any samples with a gene cycle value greater than 36
were considered of poor quality and removed. If a tumor or non-
tumor sample failed quality control from qRT-PCR that case
was removed from the analysis. All the primers for qRT-PCR in
the present study were purchased from Applied Biosystems
(Table S1).
Statistical Analysis
T-test, Wilcoxon matched-pairs t-tests, and expression graphs
were used to analyze differences in gene expression between
tumors and paired non-tumor tissues using Graphpad Prism 5.0
(Graphpad Software Inc, San Diego, California). Correlation
analysis and Kaplan-Meier analysis were performed with Graph-
pad Prism 5.0. Fisher’s exact test and Cox Proportional-hazards
regression analysis were performed using Stata 11 (StataCorp LP,
College Station, Texas). Univariate Cox regression was performed
on genes and clinical covariates to examine influence of each on
patient survival. Final multivariate models were based on stepwise
addition and removal of clinical covariates found to be associated
with survival in univariate models (P,0.05). For these models,
resection margin status was dichotomized as positive (R1) vs
negative (R0); TNM staging was dichotomized based on non-
metastatic (I-IIA) vs metastatic (IIB-IV) disease; histological grade
was dichotomized based on well and moderate differentiation
(G1&2) vs poorly differentiation(G3&4). All stepwise addition
models gave the same final models as stepwise removal models. All
univariate and multivariate Cox regression models were tested for
proportional hazards assumptions based on Schoenfeld residuals,
and no model violated these assumptions. The statistical
significance was defined as P,0.05. All P values reported were
2- sided.
Cell lines and culture conditions
Human pancreatic carcinoma cell lines Panc1 (CRL-1469
TM)
and MIApaca2 (CRL-1420
TM), were obtained from American
Type Culture Collection ATCC (Rockville, MD, USA). Cells
were maintained in GIBCOH RPMI Media 1640 supplemented
with GlutaMAX
TM-I (Invitrogen), penicillin-streptomycin
(50 IU/ml and 50 mg/ml, respectively), and 10% (v/v) fetal
calf serum (FCS). LY294002 was purchased from Cell Signaling
and dissolved in DMSO (dimethyl sulfoxide) to make 50 mM
stock solution. AZD6244 were purchased from ChemieTek and
dissolved in DMSO to make 40 mM stock solutions. Human
EGF was purchased from BD bioscience and reconstituted to
make 100 mM stock. Cells were incubated at 37uCi na
humidified atmosphere with 10% CO2. Transfection of the
plasmid was performed by using Lipofectamine LTX reagent
according to the manufacturer’s protocol (Invitrogen, USA).
Plasmid pCMV-GFP was used for transfection as the negative
control. Plasmid pCMV-DPEP1-GFP was used for DPEP1-
overexpression.
MTT assay
Cells were seeded in 96-well plates (3,000 cells/well) and
incubated for 2–10 days. Then, the MTT solution was added and
incubated for 4 hours. The solution was aspirated and 100 ul
DPEP1 and Pancreatic Cancer
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570 nm and 650 nm.
Cell invasion assay
Pancreatic cancer cell invasion assay was performed in 24-well
Biocoat Matrigel invasion chambers (8 mm; Becton Dickinson)
according to the manufacturer’s protocol. Briefly, cells were
transfected with either control vector pCMV-GFP or pCMV-
DPEP1-GFP expression vectors respectively. 24 h following
transfection, cells were harvested and plated in the top chamber
(5610
4/well). The bottom chamber contained 10% FBS as a
chemoattractant. After 48 h incubation, the noninvasive cells
were removed with a cotton swab. The invasive cells had
migrated through the membrane and stuck to the lower surface of
the membrane. GFP-positive cells were counted under a
fluorescence microscope in five fields (206 magnification). The
result is expressed as the percent invasion according to the
manufacturer’s manual: the number of the cells invading through
the Matrigel membrane divided by the number of cells migrating
through the control membrane. All assays were performed in
triplicate.
Drug cytotoxicity assay
Gemcitabine was purchased from Tocris Bioscience and
dissolved in DPBS (Dulbecco’s Phosphate-Buffered Saline) to
make 20 mM stock solution. Cells were seeded into 96-well plates
at 10,000 cells per well, allowed to grow for 24 hours, and then
treated with gemcitabine for another 96 hours. Different concen-
trations of gemcitabine were made in serum-free medium. At the
end of treatment, cell viability was determined by the CellTiter-
Glo Assay (Promega).
Results
Gene expression microarray analysis to identify
candidate genes associated with patient outcome
The characteristics of the patients with PDAC in the test cohort
(N=45, from Germany) and the validation cohort (N=27, from
Maryland) are shown in Table 1. The two cohorts were similar in
TNM staging, resection margin status, and cancer-specific
mortality (P=0.44, Kaplan-Meier log rank) with 1-year survival
rate of 64.5% for the Germany cohort and 63.0% for the
Maryland cohort. The Germany cohort was older than the
Maryland cohort (average 68.4 vs 61.9 years).
We compared gene expression profile of 45 pairs of pancreatic
tumor and adjacent non-tumor tissues in the Germany cohort
using Affymetrix GeneChip Human 1.0 ST arrays. Tumor gene
expression profiles were distinctly different from non-tumor
profiles. Using ANOVA, 2620 genes were found to be differen-
tially expressed in tumors as compared to non-tumor (P,0.001).
We next performed Cox-regression analysis and identified 277 of
the differentially expressed genes that were associated with survival
(P,0.05). The list of 277 genes was then subjected to pathway and
biomarker analyses using Ingenuity Pathways Analysis (IPA), and
36 genes were selected based on their potential association with
cancer-related pathways for further analyses (Table S1, Figure
S1A).
DPEP1 and TPX2 are associated with cancer-specific
mortality in both test and validation cohorts
We further confirmed the expression levels of these 36 genes
with qRT-PCR in tumor and non-tumor tissues in the Germany
test cohort. The microarray gene expression data and qRT-PCR
Table 1. Characteristics of population.
Germany cohort
a (n=45) Maryland cohort
b(n=27) Combined cohort (n=72) P
Age at enrollments (y) 0.003
c
Mean (SD) 68.4 (7.5) 61.9 (10.6) 65.9 (9.5)
Range 47–83 38–82 38–83
Gender, no. (%) 0.63
d
Male 21 (47) 15 (56) 36 (50)
Female 24 (53) 12 (44) 36 (50)
Resection margin, no. (%) 0.46
d
R1 23 (51) 17 (63) 40 (56)
R0 22 (49) 10 (37) 32 (44)
TNM stage, no. (%) 0.109
d
I 1 (2) 4 (15) 5 (7)
IIA 6 (14) 4 (15) 10 (15)
IIB 21 (50) 15 (58) 36 (53)
III 9 (21) 1 (4) 10 (15)
IV 5 (12) 2 (8) 7 (10)
Grading, no. (%) 0.33
d
G1&2 22 (49) 17 (63) 39 (54)
G3&4 23 (51) 10 (37) 33 (46)
aThe survival information of 3 patients was not available in German cohort, so these 3 patients were removed from analyses.
bFor one patient with liver metastasis in the Maryland cohort, the exact stage of this patient is unclear, so this patient was removed from Fisher’s exact test. Because this
patient already had liver metastasis, the tumor stage was treated as over IIB in the Cox regression.
cT-test for comparison of Gemany and Maryland cohorts.
dFisher’s exact test for comparison of Gemany and Maryland cohorts.
doi:10.1371/journal.pone.0031507.t001
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Figure.S1B). qRT-PCR results showed that 25 genes were
differentially expressed in the test cohort (P,0.01, Table S1).
The top differentially expressed transcripts between tumor and
non-tumor were TPX2, DCBLD2 and ANLN which were
significantly increased in tumors (T:N ratio.2.0, P,0.01), and
CDO1, DPEP1, C7, ALDH1A1 and NR3C2 which were significantly
decreased in tumors (T:N ratio,0.2, P,0.01).
The association of gene expression with cancer-specific
mortality in Germany test cohort was evaluated with qRT-PCR
data in which we dichotomized high and low expression for each
gene, consistent with our methods in the context of microarray
experiments for the test cohort. We found that a decreased
expression of DPEP1, or an increased expression of TPX2 and
PRR11 transcripts, was associated with poor survival (P,0.05,
Kaplan-Meier log-rank test) in the test cohort (Figure 1B).
To validate these findings, we performed qRT-PCR for these 3
genes in an independent Maryland validation cohort and analyzed
their associations with cancer-specific mortality. A lower DPEP1
expression or a higher TPX2 expression in tumor was associated
with poor survival in the Maryland validation cohort (P=0.016
and P=0.007 respectively, Kaplan-Meier log-rank test)
(Figure 2B), consistent with our results in the Germany test
cohort. PRR11 expression failed to show statistically significant
association with cancer-specific mortality in Maryland validation
cohort (Figure 2B, P=0.875).
DPEP1 expression was decreased (T: N ratio of 0.1 in test cohort
and 0.16 in validation cohort, P,0.01) and TPX2 expression was
increased (T: N ratio of 2.14 in test cohort and 2.2 in validation
cohort, P,0.001) in human pancreatic tumor tissues, as compared
with surrounding non-tumor tissues in both cohorts (Figure 1, 2).
In addition, histological grade was significantly correlated with
DPEP1 (Spearman correlation coefficient=20.35, P=0.004) or
TPX2 (Spearman correlation coefficient=0.44, P=0.0002) gene
expression (Table S2).
In order to determine the localization of DPEP1 protein, we
performed immunohistochemical staining on paraffin sections,
which showed that DPEP1 expresses in both ductal carcinoma
cells and stromal fibroblast cells (Figure S2).
DPEP1 and TPX2 are independent predictors of cancer-
specific mortality in PDAC
The Germany and Maryland cohorts were similar in gender,
resection margin status, TNM staging and overall survival.
Therefore, to increase statistical power, these cohorts were
combined for further analyses. Low DPEP1 or high TPX2
expression was associated with poor cancer-specific mortality for
all patients in the combined cohort (P,0.01, Kaplan-Meier log
rank; Figure S3A). When stratified by resection margin status
(positive vs. negative), both DPEP1 and TPX2 were associated
with cancer-specific mortality in resection margin positive
patients (P,0.01, Kaplan Meier log rank; Figure S3B).
Furthermore, TPX2 was also associated with prognosis in
resection margin-negative patients (P,0.05, Kaplan Meier log
rank; Figure S3C).
Univariate and Multivariate Cox proportional hazards analysis
was used to further evaluate the association of DPEP1 or TPX2
expression in tumors with patient outcome in the combined cohort
Figure 1. DPEP1, TPX2 and PRR11 expression are associated with cancer-specific death in test Germany cohort. A: DPEP1 was
expressed at a lower level and TPX2 at a higher level in pancreatic tumors as compared to adjacent non-tumor tissue. Dot plots represent gene
expression level with relative threshold cycle value (Ct) normalized with endogenous control gene GAPDH. Bars indicate median value. Wilcoxon
matched-pairs t-tests P value and tumor: non-tumor ratios (T:N) are indicated in the graphs. B: Kaplan Meier analysis of DPEP1, TPX2, and PRR11 in
the Germany test cohort.
doi:10.1371/journal.pone.0031507.g001
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survival after surgery are the stage, grade, and the resection
margin status. Resection margin status was confirmed as an
influential prognostic factor in many studies [13]. In our study,
Univariate Cox regression analysis for all cases found that high
DPEP1 (hazard ratio (HR), 0.42; 95% CI, 0.24–0.76; P=0.004),
high TPX2 (HR, 2.92; 95% CI, 1.57–5.40; P=0.001), and
resection margin positive status (HR, 1.77; 95% CI, 0.99–3.18;
P=0.05) were each associated with prognosis but not the tumor
stage or grade (Table 2). Multivariate analyses showed that both
high DPEP1 (HR, 0.51; 95% CI, 0.27–0.96) and high TPX2 (HR,
2.42; 95% CI, 1.27–4.61) were independent of one another and
resection margin status. Additionally, the final multivariate model
including DPEP1, TPX2 and resection margin did significantly
better than a model without TPX2 or DPEP1 (P=0.012 or
P=0.036 respectively, likelihood ratio test). Therefore, the
combination of resection margin status, DPEP1 and TPX2
expression is significantly better at predicting patient outcome in
Figure 2. Validation of DPEP1 and TPX2 in independent Maryland cohort. A: DPEP1 and TPX2 were differentially expressed in Maryland
validation cohort at a similar level as in Germany cohort. Dot plots represent gene expression level with relative threshold cycle value (Ct) normalized
with endogenous control gene GAPDH. Bars indicate median value. Wilcoxon matched-pairs t-tests P value and tumor: non-tumor ratios (T:N) are
indicated in the graphs. B: The association of DPEP1 or TPX2 with patient survival was validated in the Maryland cohort. PRR11 was not associated
with survival in the validation cohort.
doi:10.1371/journal.pone.0031507.g002
Table 2. Cox regression analysis of DPEP1 and TPX2 expression with caner-specific mortality on combined Germany test cohort
and Maryland validation cohort.
Variables (comparison/referent) Univariate analysis
a Multivariate analysis
b
HR (95% CI) P HR (95% CI) P
DPEP1(high/low) 0.43 (0.24–0.76) 0.004 0.51 (0.27–0.94) 0.032
TPX2(high/low) 2.92 (1.57–5.40) 0.001 2.42 (1.27–4.61) 0.007
Resection Margin (R1/R0) 1.77 (0.99–3.18) 0.050 1.90 (1.05–3.45) 0.033
Grading (G3&4/1&2) 1.72 (0.97–3.04) 0.063
Tumor stage (IIB-IV/I-IIA) 1.58 (0.80–3.13) 0.191
aUnivariate analysis is adjusted for cohort membership only.
bMultivariate analysis is adjusted for cohort membership, TPX2, DPEP1, and resection margin status. Multivariate analysis used stepwise addition and removal of clinical
covariates found to be associated with survival in Univariate model and final models include only those covariates that were significantly associated with survival
(P,0.05).
doi:10.1371/journal.pone.0031507.t002
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ing their clinical significance.
Overexpression of DPEP1 inhibits cell invasion in vitro
The oncogenic role of TPX2 in pancreatic cancer develop-
ment has been demonstrated in previous studies [14].
However, the biological function of DPEP1 in PDAC remains
unknown. Therefore, we examined if the expression of DPEP1
affects the cellular growth and invasion of pancreatic cancer
cell lines. Cell lines that were transfected with pCMV-DPEP1-
GFP showed enhanced expression of DPEP1 as compared with
control pCMV-GFP transfectants in Panc1 and MIApaca2
respectively (Figure S4 A&B). DPEP1 overexpression had no
effect on cell proliferation and colony formation in Panc1 and
MIApaca2 cells (Figure S4 C&D). We then compared the
invasive ability of DPEP1 cDNA transfectants and control GFP
transfectants in Panc1 and MIApaca2 cells using 10% FBS as a
chemoattractant in Matrigel invasion assays. DPEP1 overex-
pressing cells showed markedly decreased invasive ability
compared with control cells in both Panc1 and MIApaca2
cells (P,0.01, Figure 3).
DPEP1 sensitizes pancreatic cancer cells to Gemcitabine
Rapid development of resistance in PDAC inevitably translates
into poor patient outcomes [15]. To determine the effect of
DPEP1 expression on the sensitivity of pancreatic cancer cell lines
to gemcitabine, we examined cytotoxicity of gemcitabine on Panc1
and MIApaca2 cells after 96 h of drug exposure. We found that
the relative cytotoxicity to gemcitabine at 0.2 mM for GFP control
and DPEP1 transfectants were 25% and 44% respectively in
Panc1 cells (Figure 4A, P,0.01). The sensitivity of MIApaca2 cells
to lower dose of gemcitabine (0.06 mM) is also increased by
DPEP1 overexpression as compared to control cells (50% vs 28%
of cytotoxicity, Figure 4B). These results demonstrated that
DPEP1 overexpression significantly increased the sensitivity to
gemcitabine (P,0.01) in pancreatic cancer cells.
Figure 3. DPEP1 overexpression inhibits cell invasion in Panc1 and MIApaca2 cells. A: Cell invasion was analyzed in Panc1 (upper panel) and
MIApaca2 (lower panel) cells using Biocoat matrigel invasion assay. The invaded GFP-positive cells were counted under a fluorescence microscope. B:
Relative cell invasion is expressed as the ratio of the percent invasion of a test cell over the percent invasion of a control cell (* P,0.01).
doi:10.1371/journal.pone.0031507.g003
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Growth factor EGF can activate RAS-RAF-MEK-ERK as well
as PI3K pathways [16]. High level of EGF and constitutive
activation of the RAS-RAF-MEK-ERK pathway was found in
pancreatic cancer. To investigate the possible mechanism for the
regulation of DPEP1 expression in pancreatic cancer, we
examined the levels of DPEP1 in Panc1 cells in response to
EGF (30 nM), MEK1/2 inhibitor AZD6244 (1.5 mM) and PI3K
inhibitor LY294002 (1.5 mM).
Treatment with EGF significantly decreased DPEP1 by about
50% (P,0.01). The inhibition of DPEP1 expression by EGF was
rescued by AZD6244 (MEK1/2 inhibitor) but not LY294002
(PI3K inhibitor) (Figure 5A and B). A significant increase (,2 fold)
in DPEP1 gene expression was also found when cells were treated
with AZD6244 alone (P,0.01) in 24 h (Figure 5A and Figure S5).
However, LY294002 alone had no effect on DPEP1 expression.
Western blot demonstrated the efficiency and specificity of
AZD6244 and LY294002 (Figure 5C). These data indicate that
MEK/ERK pathway but not PI3K pathway is involved in
regulating DPEP1 expression in pancreatic cancer.
Discussion
To identify biologically-relevant genes with therapeutic poten-
tial for PDAC, we first identified genes that were associated with
cancer-specific mortality by microarray gene expression analysis
and validated them by qRT-PCR in two independent cohorts of
resected PDAC cases. We demonstrated that low DPEP1
expression is significantly associated with poor survival in the
Germany test cohort and the Maryland validation cohort.
Multivariate analysis showed that the association of DPEP1 with
cancer-specific mortality was independent of resection margin
status. We also found a negative correlation of DPEP1 gene
expression with histological grade (Spearman correlation coeffi-
cient=20.35, P=0.004). To our knowledge, our data for the first
time suggested that DPEP1 may be a useful prognostic indicator,
in addition to resection margin status, for PDAC patients following
resection. Our study showed a marked reduction in DPEP1
expression in pancreatic tumors as compared with non-tumor
tissues using both microarray and qPCR, which is consistent with
the ONCOMINE data mining [17]. Earlier reports have provided
evidence for altered expression of DPEP1 in various malignancies
[18,19]. Loss of DPEP1 expression was associated with breast
cancer and Wilms’ tumor [20,21]. However, DPEP1 is highly
expressed in colon tumors compared to matched normal mucosa
[22]. In addition to DPEP1, we also found that higher TPX2
expression is associated with poor outcome in two independent
cohorts of resected PDAC patients, supporting the oncogenic role
of TPX2 in several solid tumors including pancreatic adenocar-
cinoma [23,24].
The fact that a higher DPEP1 expression level is associated with
better patient outcome indicated its possible inhibitory role in
tumor aggressiveness. In the present study, we have elucidated the
function of DPEP1 in pancreatic cancer cells. Our data showed
that DPEP1 overexpression in pancreatic cancer cell lines
significantly inhibits cell invasion (Figure 3) but has no effect on
cell proliferation and tumor colony formation (Figure S4 C and D).
Moreover, DPEP1 over-expression increases the sensitivity of
pancreatic cancer cells to chemotherapeutic drug gemcitabine.
The molecular mechanism by which DPEP1 inhibits tumor
progression and aggressiveness is not known. Interestingly,
immunostaining of archival human pancreatic cancer tissues
showed DPEP1 expression in both carcinoma cells and peritu-
moral stroma. Future studies will investigate whether DPEP1 in
stromal cells plays a role in pancreatic cancer development.
DPEP1 is also implicated in the metabolism of glutathione, an
important antioxidant [20,21], which helps in maintaining the
optimal redox state in the cellular microenvironment and protect
cells against pathological stress. Reduced DPEP1 expression leads
to dysregulation of glutathione homeostasis, which may promote
tumorigenesis [25].
Given the association of high DPEP1 with a better outcome in
pancreatic cancer and its potential role in inhibiting tumor
Figure 4. DPEP1 overexpression enhances sensitivity to
gemcitabine. DPEP1 overexpressing cells and control cells were
analyzed for cellular sensitivity to gemcitabine using Panc1 (A) and
MIApaca2 (B). Overexpession of DPEP1 increased the sensitivity of
Panc1 and MIApaca2 cells to gemcitabine. Control cells are Panc1 or
MIApaca2 cells transfected with GFP control vectors. Cells were treated
with Gemcitabine for 96 hours at different doses. The MTS assay was
used to quantitate cytotoxicity (cell death) according to the manufac-
turer’s instructions. Relative cytotoxicity (%) was calculated using the
formula: [12(OD570 of drug treated cells/OD570 of untreated
cells)]6100%. Data are means 6 S.D. from 3 independent experiments.
* T-test P,0.01.
doi:10.1371/journal.pone.0031507.g004
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increase DPEP1, may improve patients’ survival. In this study we
found that EGF/RAS/MEK pathway is involved in regulating
DPEP1 expression. Inhibition of MEK/ERK pathway by
AZD6244 increases DPEP1 level in Panc1 cells. AZD6244 is a
potent and selective MEK inhibitor that has been selected for
clinical development because of its potency and favorable
pharmacokinetic profile [26]. Further delineation of pathways
that regulate DPEP1 expression in pancreatic cancer may provide
insights into the genes and pathways associated with DPEP1 and
facilitate the development of more effective therapeutic strategies
for PDAC.
In conclusion, we showed for the first time that DPEP1 is a
significant predictor for patient outcome in resected PDAC cases.
Functional evidence that DPEP1 inhibits cancer cell invasion and
enhances sensitivity to gemcitabine, suggests DPEP1 as a
candidate target for designing therapeutic strategies.
Supporting Information
Figure S1 A: Network analysis was preformed to provide a
graphical representation of 36 genes selected from microarray
analysis using IPA. Genes in this top network are associated with
cancer, cell cycle, and cellular movement. Green icons indicate
downregulated genes and red indicates upregulated genes. P value
and fold change of gene expression comparison were labeled
under each gene symbol. B: Correlation of the tumor vs.
nontumor tissue expression ratios, comparing the qRT-PCR data
with microarray data in the Germany test cohort. Human
GAPDH was used as endogenous control for qRT-PCR to
normalize across the samples. Spearman correlation test r=0.89,
P,0.0001.
(TIF)
Figure S2 Representative immunostaining of different
levels of DPEP1 expression in two primary PDAC
archived samples from tissue microarray slides.
(TIF)
Figure S3 Combined analysis of Germany test and
Maryland validation cohorts. Germany test and Maryland
validation cohorts were combined together to increase statistical
power. A: Kaplan Meier analysis of DPEP1 and TPX2 in
combined cohort. B: Kaplan Meier analysis of DPEP1 and TPX2
stratified by resection margin status. R1: patients with positive
microscopic resection margins; R0: patients with negative
resection margins.
(TIF)
Figure S4 Effect of DPEP1 on pancreatic cancer cell
proliferation and colony formation. Cell proliferation of
Panc1 and MIApaca2 cells monitored by MTT assay from day 2
to day 10. Increased expression of DPEP1 in transfected cells were
demonstrated by quantitative RT-PCR (A) and western blot (B).
There was no significant difference between DPEP1 overexpress-
ing cells and control cells (P.0.1) in cell growth (C) and colony
formation (D).
(TIF)
Figure S5 DPEP1 mRNA level at different time points
(6 h, 12 h, 24 h and 48 h) after adding AZD6244. Real-
time PCR was done to determine DPEP1 mRNA levels. Relative
expression of DPEP1 represents the effect of treatment on gene
expression compared to untreated control. Data are means 6 S.D.
from 3 independent experiments. * T-test P,0.01.
(TIF)
Figure 5. Effect of EGF, AZD6244 and LY294002 on DPEP1
expression. Panc1 cells were starved in 0.1% FBS for 16 hours before
treatments. Cells were treated with RPMI medium containing EGF
(30 ng/mL), AZD6244 (1.5 mM) or LY294002 (1.5 mM) alone for 24 hours.
EGF+AZD6244 or EGF+LY294002: Panc1 ells were pretreated with
AZD6244 or LY294002 for 1 h prior to the addition of EGF. Untreated
control cells were maintained in RPMI with DMSO. A: Real-time PCR was
done to determine DPEP1 mRNA levels. Ratio of DPEP1expression
represents the effect of treatment on gene expression compared to
untreated control. Data are means 6 S.D. from 3 independent
experiments. * T-test P,0.01. B: Western blot showed similar changes
at protein level of DPEP1 after 24 hour treatment. C: Western blot
demonstrated the efficiency and specificity of AZD6244 and LY294002.
doi:10.1371/journal.pone.0031507.g005
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analysis and evaluated by RT-PCR in Germany test
cohort.
(DOC)
Table S2 Correlation of histological grade, stage or
resection margin with DPEP1 or TPX2 gene expression.
(DOC)
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